Work

Acquired Substrate Preference for GAB1 Protein Bestows Transforming Activity to ERBB2 Kinase Lung Cancer Mutants

Year: 2013

Type: article

Abstract: Activating mutations in the αC-β4 loop of the ERBB2 kinase domain, such as ERBB2 YVMA and ERBB2 G776VC , have been identified in human lung cancers and found to drive tumor formation. Here we observe that the docking protein GAB1 is hyper-phosphorylated in carcinomas from transgenic mice and in cell lines expressing these ERBB2 cancer mutants. Using dominant negative GAB1 mutants lacking canonical tyrosine residues for SHP2 and PI3K interactions or lentiviral shRNA that targets GAB1, we demonstrate that GAB1 phosphorylation is required for ERBB2 mutant-induced cell signaling, cell transformation, and tumorigenesis. An enzyme kinetic analysis comparing ERBB2 YVMA to wild type using physiologically relevant peptide substrates reveals that ERBB2 YVMA kinase adopts a striking preference for GAB1 phosphorylation sites as evidenced by ∼150-fold increases in the specificity constants ( k cat / K m ) for several GAB1 peptides, and this change in substrate selectivity was predominantly attributed to the peptide binding affinities as reflected by the apparent K m values. Furthermore, we demonstrate that ERBB2 YVMA phosphorylates GAB1 protein ∼70-fold faster than wild type ERBB2 in vitro . Notably, the mutation does not significantly alter the K m for ATP or sensitivity to lapatinib, suggesting that, unlike EGFR lung cancer mutants, the ATP binding cleft of the kinase is not significantly changed. Taken together, our results indicate that the acquired substrate preference for GAB1 is critical for the ERBB2 mutant-induced oncogenesis. Background: Activating ERBB2 mutants drive tumor formation. Results: Oncogenic ERBB2 has a striking substrate preference for GAB1 in vitro , and GAB1 hyper-phosphorylation is required for mutant ERBB2-induced cell signaling and transformation. Conclusion: Acquired substrate preference for GAB1 is critical to the ERBB2 mutant-mediated oncogenesis. Significance: Understanding the activation mechanism of mutant ERBB2s may lead to the development of therapies targeted against these oncogenic kinases.

Source: Journal of Biological Chemistry

DOI: 10.1074/jbc.m112.434217